Inder Singal, MD
Ophthalmology · Louisville, KYNPI 1922082072
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Regeneron Healthcare Solutions, Inc. accounts for 64.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $5,152 and has fallen 91.3% since, to $449 in 2025. Among ophthalmology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $59.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$6K
- Alcon$692
- Genentech USA, Inc.$646
- AbbVie$378
- Novartis$291
- Apellis Pharmaceuticals, Inc.$281
- plus $1K from 14 others
What the payments were for
- Consulting fees$4,86553%
- Food & beverage$4,36247%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 36 | $5,949 |
| Alcon | 16 | $692 |
| Genentech USA, Inc. | 25 | $646 |
| AbbVie(2 entities) | 19 | $378 |
| Novartis | 12 | $291 |
| Apellis Pharmaceuticals, Inc. | 10 | $281 |
| ANI Pharmaceuticals, Inc. | 5 | $204 |
| Biogen | 6 | $155 |
| Astellas Pharma US Inc | 6 | $121 |
| Mallinckrodt Hospital Products Inc. | 3 | $100 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $97 |
| Genentech, Inc. | 2 | $96 |
| Glaukos Corporation | 1 | $55 |
| Alimera Sciences, Inc. | 2 | $45 |
| Biotissue Holdings Inc. | 2 | $44 |
| Oyster Point Pharma, Inc. | 2 | $32 |
| Harrow Eye, LLC | 1 | $23 |
| Amgen | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Ivantis, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$5,122
- VABYSMO$272
- Syfovre$145
- ReSTOR$136
- ACTIVEFOCUS$127
- Clareon$109
- EYLEA HD$105
- PURIFIED CORTROPHIN GEL$104
How this compares
$9,264 in reported general payments places this provider in the 90th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 122 | $28,602 |
| Prednisolone Acetate | 303 | $11,714 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $11,258 |
| LumiganBimatoprost | 38 | $10,985 |
| RestasisCyclosporine | 15 | $10,952 |
| RhopressaNetarsudil Mesylate | 33 | $10,211 |
| MoxifloxacinMoxifloxacin Hcl | 227 | $6,406 |
| Ofloxacin | 326 | $4,588 |
| VyzultaLatanoprostene Bunod | 14 | $3,683 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $2,357 |
| Timolol Maleate | 80 | $1,354 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 100 | $1,116 |
| Latanoprost | 153 | $1,108 |
| Fluorometholone | 16 | $1,098 |
| Brimonidine Tartrate | 142 | $756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Restasis | $378 | $50,538175 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $17 | $21,46957 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Louisville
- Jeremy ClarkLouisville$131K
- Guruprasad PattarLouisville$36K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
- Rishi KumarLouisville$8K
- Frank BurnsLouisville$8K
- Steven BloomLouisville$6K
- Sharmini BalakrishnanLouisville$6K
- Sergei DmitrukLouisville$5K
- Lawrence TenkmanLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.